- Share this link: https://changedetection.io/share/xHpz4LQnthMa
Differences
Pro-tip: Use show current snapshot tab to visualise what will be ignored.
* Home * About * Portfolio * Meet the Team * News * Contact * Investor Portal * info@chv.vc * 129 South Street, 4th Floor, Boston, MA 02111 * Home / News News & Updates Featured Story Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain * May 14, 2024 * - * Brixton Biosciences Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection * April 23, 2024 * - * Epitel Select a Company Allegro Diagnostics (1) Aria CV (5) AtaCor Medical (4) Augmenix (1) Biocius (1) BioTrove (1) Conformal (13) GI Dynamics (1) Sera Prognostics (26) nVision (1) Maxwell Health (1) Vortex Medical (1) Novazyme Pharmaceuticals (1) Saphena Medical (3) Brixton Biosciences (2) PanTher Therapeutics (5) Instylla Inc. (3) Catalyst Health Ventures (2) Epitel (3) Avive (2) Rejoni (1) The Latest Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain * May 14, 2024 * - * Brixton Biosciences Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection * April 23, 2024 * - * Epitel Avive Solutions Raises $56.5M in Growth Funding To Build Connected AED Network and Transform Cardiac Arrest Emergency Response in Communities Nationwide * April 18, 2024 * - * Avive Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System * February 27, 2024 * - * Aria CV Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success * December 6, 2023 * - * Sera Prognostics BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA * October 26, 2023 * - * Brixton Biosciences Conformal Medical Raises $35 Million in Oversubscribed Series D Round * June 6, 2023 * - * Conformal Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO * May 15, 2023 * - * Sera Prognostics Show More Let’s Connect. Contact Us Sitemap * Home * About * Portfolio * Meet the Team * News * Contact * Investor Portal About Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs. Contact * info@chv.vc Boston Web Design by GoingClear | * Home * About * Portfolio * Meet the Team * News * Contact * Investor Portal * info@chv.vc * 129 South Street, 4th Floor, Boston, MA 02111 * Home / News News & Updates Featured Story Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors * June 26, 2024 * - * Epitel Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain * May 14, 2024 * - * Brixton Biosciences Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection * April 23, 2024 * - * Epitel Select a Company Allegro Diagnostics (1) Aria CV (5) AtaCor Medical (4) Augmenix (1) Biocius (1) BioTrove (1) Conformal (13) GI Dynamics (1) Sera Prognostics (26) nVision (1) Maxwell Health (1) Vortex Medical (1) Novazyme Pharmaceuticals (1) Saphena Medical (3) Brixton Biosciences (2) PanTher Therapeutics (5) Instylla Inc. (3) Catalyst Health Ventures (2) Epitel (4) Avive (2) Rejoni (1) The Latest Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors * June 26, 2024 * - * Epitel Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain * May 14, 2024 * - * Brixton Biosciences Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection * April 23, 2024 * - * Epitel Avive Solutions Raises $56.5M in Growth Funding To Build Connected AED Network and Transform Cardiac Arrest Emergency Response in Communities Nationwide * April 18, 2024 * - * Avive Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System * February 27, 2024 * - * Aria CV Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success * December 6, 2023 * - * Sera Prognostics BRIXTON BIOSCIENCES’ COOLIO™ THERAPY GRANTED BREAKTHOUGH DEVICE DESIGNATION BY FDA * October 26, 2023 * - * Brixton Biosciences Conformal Medical Raises $35 Million in Oversubscribed Series D Round * June 6, 2023 * - * Conformal Show More Let’s Connect. Contact Us Sitemap * Home * About * Portfolio * Meet the Team * News * Contact * Investor Portal About Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs. Contact * info@chv.vc Boston Web Design by GoingClear |
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires Playwright/WebDriver enabled